Strontium ranelate does not stimulate bone formation in ovariectomized rats

R. K. Fuchs, Matthew Allen, K. W. Condon, S. Reinwald, L. M. Miller, D. McClenathan, B. Keck, R. J. Phipps, David Burr

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Introduction: Strontium ranelate (SrR) is suggested to function as a dual-acting agent in the treatment of postmenopausal osteoporosis with anti-resorptive and anabolic skeletal benefits. We evaluated the effects of SrR on the skeleton in ovariectomized (OVX) rats and evaluated the influence of dietary calcium. Methods: Three-month old virgin female rats underwent ovariectomy (OVX, n=50) or SHAM surgery (SHAM, n=10). Four weeks post-surgery, rats were treated daily by oral gavage with distilled water (10 ml/kg/day) or SrR (25 or 150 mg/kg/day) for 90 days. Separate groups of animals for each dose of SrR were fed a low (0.1%) or normal (1.19%) calcium (Ca) diet. Static and dynamic histomorphometry, DXA, μ-CT, mechanical testing, and serum and skeletal concentrations of strontium were assessed. Results: SrR at doses of 25 and 150 mg/kg/day did not increase bone formation on trabecular or periosteal bone surfaces, and failed to inhibit bone resorption of trabecular bone regardless of Ca intake. There were no improvements in bone mass, volume or strength with either dose of SrR given normal Ca. Conclusion: These findings demonstrate that SrR at dosages of 25 and 150 mg/kg/day did not stimulate an anabolic bone response, and failed to improve the bone biomechanical properties of OVX rats.

Original languageEnglish
Pages (from-to)1331-1341
Number of pages11
JournalOsteoporosis International
Volume19
Issue number9
DOIs
StatePublished - Sep 2008

Fingerprint

strontium ranelate
Osteogenesis
Bone and Bones
Calcium
Dietary Calcium
Strontium
Postmenopausal Osteoporosis
Ovariectomy
Bone Resorption
Skeleton

Keywords

  • Animal model
  • Bone mineralization
  • Bone strength
  • Calcium
  • Osteoporosis
  • Strontium ranelate

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fuchs, R. K., Allen, M., Condon, K. W., Reinwald, S., Miller, L. M., McClenathan, D., ... Burr, D. (2008). Strontium ranelate does not stimulate bone formation in ovariectomized rats. Osteoporosis International, 19(9), 1331-1341. https://doi.org/10.1007/s00198-008-0602-6

Strontium ranelate does not stimulate bone formation in ovariectomized rats. / Fuchs, R. K.; Allen, Matthew; Condon, K. W.; Reinwald, S.; Miller, L. M.; McClenathan, D.; Keck, B.; Phipps, R. J.; Burr, David.

In: Osteoporosis International, Vol. 19, No. 9, 09.2008, p. 1331-1341.

Research output: Contribution to journalArticle

Fuchs, RK, Allen, M, Condon, KW, Reinwald, S, Miller, LM, McClenathan, D, Keck, B, Phipps, RJ & Burr, D 2008, 'Strontium ranelate does not stimulate bone formation in ovariectomized rats', Osteoporosis International, vol. 19, no. 9, pp. 1331-1341. https://doi.org/10.1007/s00198-008-0602-6
Fuchs, R. K. ; Allen, Matthew ; Condon, K. W. ; Reinwald, S. ; Miller, L. M. ; McClenathan, D. ; Keck, B. ; Phipps, R. J. ; Burr, David. / Strontium ranelate does not stimulate bone formation in ovariectomized rats. In: Osteoporosis International. 2008 ; Vol. 19, No. 9. pp. 1331-1341.
@article{57e2172127d94f57aa75a1e8a7c9ce3b,
title = "Strontium ranelate does not stimulate bone formation in ovariectomized rats",
abstract = "Introduction: Strontium ranelate (SrR) is suggested to function as a dual-acting agent in the treatment of postmenopausal osteoporosis with anti-resorptive and anabolic skeletal benefits. We evaluated the effects of SrR on the skeleton in ovariectomized (OVX) rats and evaluated the influence of dietary calcium. Methods: Three-month old virgin female rats underwent ovariectomy (OVX, n=50) or SHAM surgery (SHAM, n=10). Four weeks post-surgery, rats were treated daily by oral gavage with distilled water (10 ml/kg/day) or SrR (25 or 150 mg/kg/day) for 90 days. Separate groups of animals for each dose of SrR were fed a low (0.1{\%}) or normal (1.19{\%}) calcium (Ca) diet. Static and dynamic histomorphometry, DXA, μ-CT, mechanical testing, and serum and skeletal concentrations of strontium were assessed. Results: SrR at doses of 25 and 150 mg/kg/day did not increase bone formation on trabecular or periosteal bone surfaces, and failed to inhibit bone resorption of trabecular bone regardless of Ca intake. There were no improvements in bone mass, volume or strength with either dose of SrR given normal Ca. Conclusion: These findings demonstrate that SrR at dosages of 25 and 150 mg/kg/day did not stimulate an anabolic bone response, and failed to improve the bone biomechanical properties of OVX rats.",
keywords = "Animal model, Bone mineralization, Bone strength, Calcium, Osteoporosis, Strontium ranelate",
author = "Fuchs, {R. K.} and Matthew Allen and Condon, {K. W.} and S. Reinwald and Miller, {L. M.} and D. McClenathan and B. Keck and Phipps, {R. J.} and David Burr",
year = "2008",
month = "9",
doi = "10.1007/s00198-008-0602-6",
language = "English",
volume = "19",
pages = "1331--1341",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "9",

}

TY - JOUR

T1 - Strontium ranelate does not stimulate bone formation in ovariectomized rats

AU - Fuchs, R. K.

AU - Allen, Matthew

AU - Condon, K. W.

AU - Reinwald, S.

AU - Miller, L. M.

AU - McClenathan, D.

AU - Keck, B.

AU - Phipps, R. J.

AU - Burr, David

PY - 2008/9

Y1 - 2008/9

N2 - Introduction: Strontium ranelate (SrR) is suggested to function as a dual-acting agent in the treatment of postmenopausal osteoporosis with anti-resorptive and anabolic skeletal benefits. We evaluated the effects of SrR on the skeleton in ovariectomized (OVX) rats and evaluated the influence of dietary calcium. Methods: Three-month old virgin female rats underwent ovariectomy (OVX, n=50) or SHAM surgery (SHAM, n=10). Four weeks post-surgery, rats were treated daily by oral gavage with distilled water (10 ml/kg/day) or SrR (25 or 150 mg/kg/day) for 90 days. Separate groups of animals for each dose of SrR were fed a low (0.1%) or normal (1.19%) calcium (Ca) diet. Static and dynamic histomorphometry, DXA, μ-CT, mechanical testing, and serum and skeletal concentrations of strontium were assessed. Results: SrR at doses of 25 and 150 mg/kg/day did not increase bone formation on trabecular or periosteal bone surfaces, and failed to inhibit bone resorption of trabecular bone regardless of Ca intake. There were no improvements in bone mass, volume or strength with either dose of SrR given normal Ca. Conclusion: These findings demonstrate that SrR at dosages of 25 and 150 mg/kg/day did not stimulate an anabolic bone response, and failed to improve the bone biomechanical properties of OVX rats.

AB - Introduction: Strontium ranelate (SrR) is suggested to function as a dual-acting agent in the treatment of postmenopausal osteoporosis with anti-resorptive and anabolic skeletal benefits. We evaluated the effects of SrR on the skeleton in ovariectomized (OVX) rats and evaluated the influence of dietary calcium. Methods: Three-month old virgin female rats underwent ovariectomy (OVX, n=50) or SHAM surgery (SHAM, n=10). Four weeks post-surgery, rats were treated daily by oral gavage with distilled water (10 ml/kg/day) or SrR (25 or 150 mg/kg/day) for 90 days. Separate groups of animals for each dose of SrR were fed a low (0.1%) or normal (1.19%) calcium (Ca) diet. Static and dynamic histomorphometry, DXA, μ-CT, mechanical testing, and serum and skeletal concentrations of strontium were assessed. Results: SrR at doses of 25 and 150 mg/kg/day did not increase bone formation on trabecular or periosteal bone surfaces, and failed to inhibit bone resorption of trabecular bone regardless of Ca intake. There were no improvements in bone mass, volume or strength with either dose of SrR given normal Ca. Conclusion: These findings demonstrate that SrR at dosages of 25 and 150 mg/kg/day did not stimulate an anabolic bone response, and failed to improve the bone biomechanical properties of OVX rats.

KW - Animal model

KW - Bone mineralization

KW - Bone strength

KW - Calcium

KW - Osteoporosis

KW - Strontium ranelate

UR - http://www.scopus.com/inward/record.url?scp=49549101612&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49549101612&partnerID=8YFLogxK

U2 - 10.1007/s00198-008-0602-6

DO - 10.1007/s00198-008-0602-6

M3 - Article

VL - 19

SP - 1331

EP - 1341

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 9

ER -